Last reviewed · How we verify
Penehyclidine inhalation
Penehyclidine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce airway secretions and bronchospasm.
Penehyclidine is an anticholinergic agent that blocks muscarinic acetylcholine receptors to reduce airway secretions and bronchospasm. Used for Acute airway obstruction and bronchospasm, Organophosphate or nerve agent poisoning (anticholinergic effects).
At a glance
| Generic name | Penehyclidine inhalation |
|---|---|
| Also known as | Penehyclidine Hydrochloride for Injection (Changtuoning) |
| Sponsor | Peking University First Hospital |
| Drug class | Anticholinergic bronchodilator |
| Target | Muscarinic acetylcholine receptors (M1, M3) |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Penehyclidine acts as a selective M1 and M3 muscarinic receptor antagonist, reducing parasympathetic-mediated bronchoconstriction and excessive mucus production in the airways. When administered via inhalation, it provides rapid local effects on airway smooth muscle and secretory glands, making it useful for managing acute respiratory conditions characterized by bronchospasm and hypersecretion.
Approved indications
- Acute airway obstruction and bronchospasm
- Excessive airway secretions in respiratory conditions
Common side effects
- Dry mouth
- Tremor
- Tachycardia
- Dizziness
Key clinical trials
- Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia (PHASE4)
- Prophylactic Penehyclidine Hydrochloride Inhalation and 3-year Outcome After Surgery (PHASE4)
- Preventive Effects of Penehyclidine Hydrochloride Inhalation on Postoperative Pulmonary Complications (PHASE4)
- Effect of Induction and Maintenance of Anesthesia With Etomidate on Hemodynamics and Oxidative Stress in Diabetic Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Penehyclidine inhalation CI brief — competitive landscape report
- Penehyclidine inhalation updates RSS · CI watch RSS
- Peking University First Hospital portfolio CI